Inventor · disambiguated record
Christoph Müller
Also filed as: MULLER CHRISTOPH · MÜLLER CHRISTOPH ANTON · MüLLER CHRISTOPH
11 granted patents·10 pending applications·22 citations·filing 2010–2025
85Inventor score
Files withHEIDELBERG PHARMA RES GMBH12HEIDELBERG PHARMA GMBH2HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH2SIMON WERNER2ACADEMISCH ZIEKENHUIS LEIDEN1
Top patents by PatentIndex Score
21 records- 0186US10842882B2Amatoxin-antibody conjugatesHEIDELBERG PHARMA GMBH·Filed 2016·Granted Nov 24, 2020·5 cites·9 claims
- 0279US9233173B2Amatoxin-armed therapeutic cell surface binding components designed for tumour therapyFAULSTICH HEINZ·Filed 2010·Granted Jan 12, 2016·11 cites·20 claims
- 0375US11420971B2Method for synthesizing amanitinsHEIDELBERG PHARMA RES GMBH·Filed 2018·Granted Aug 23, 2022·1 cites·8 claims
- 0475US10961277B2Method for synthesizing amanitinsHEIDELBERG PHARMA RES GMBH·Filed 2018·Granted Mar 30, 2021·1 cites·9 claims
- 0573US11590238B2Amanitin conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2017·Granted Feb 28, 2023·1 cites·6 claims
- 0672US2025009901A1Composition comprising a combination of immune checkpoint inhibitor and antibody-amatoxin conjugate for use in cancer therapyHEIDELBERG PHARMA RES GMBH·Filed 2024·Application pending·0 cites
- 0770US11926631B2Method of treating cancer using amanitin derivativesHEIDELBERG PHARMA RES GMBH·Filed 2022·Granted Mar 12, 2024·0 cites·4 claims
- 0870US9982018B2Amatoxin derivativesHEIDELBERG PHARMA GMBH·Filed 2014·Granted May 29, 2018·2 cites·24 claims
- 0968US11446388B2Amanitin antibody conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2017·Granted Sep 20, 2022·1 cites·3 claims
- 1065US12378196B2Synthesis of (S)-6-hydroxytryptophan and derivatives thereofHEIDELBERG PHARMA RES GMBH·Filed 2019·Granted Aug 5, 2025·0 cites·16 claims
- 1164US11702451B2Method for synthesizing amanitinsHEIDELBERG PHARMA RES GMBH·Filed 2021·Granted Jul 18, 2023·0 cites·20 claims
- 1261US2022133902A1Composition Comprising a Combination of Immune Checkpoint Inhibitor and Antibody-Amatoxin Conjugate for Use in Cancer TherapyHEIDELBERG PHARMA RES GMBH·Filed 2021·Application pending·0 cites
- 1355US2025179018A1Synthesis of (s)-6-hydroxytryptophan and derivatives thereofHEIDELBERG PHARMA RES GMBH·Filed 2025·Application pending·0 cites
- 1454US2018185509A1Amatoxin-conjugates with improved linkagesSIMON WERNER·Filed 2017·Application pending·0 cites
- 1554US2024316187A1Proteins identified from barn dust extract for the prevention and treatment of diseasesHELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH·Filed 2022·Application pending·0 cites
- 1654US2014294865A1Amatoxin-conjugates with improved linkagesSIMON WERNER·Filed 2012·Application pending·0 cites
- 1752US2024082416A1Amatoxin analogs and uses thereofUNIV BRITISH COLUMBIA·Filed 2021·Application pending·0 cites
- 1852US2025312355A1Dhcr24 inhibitory compoundsACADEMISCH ZIEKENHUIS LEIDEN·Filed 2023·Application pending·0 cites
- 1949US10723766B2Derivatives of gamma-amanitinHEIDELBERG PHARMA RES GMBH·Filed 2016·Granted Jul 28, 2020·0 cites·4 claims
- 2048US2025195678A1B-lymphocyte specific amatoxin antibody conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2020·Application pending·0 cites
- 2143US2022047630A1Barn dust extract for the prevention and treatment of diseasesHELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christoph Müller files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →